While the efficacy of EZH2 inhibitors has been described in ongoing clinical trials, we provide the first insight into the mechanism of EZH2 inhibition-induced tumor cell death and show evidence of a possible resistance mechanism in an INI-1 deficient P-ES PDX. This evidence concerns the gene EZH2 and neoplasm.